• Teva Page Title

Korporativne novice

Opomba: novice so v angleškem jeziku, povezave vodijo na korporativno stran podjetja Teva.

17.05.2017

Teva Showcases Asthma Research at the 2017 American Thoracic Society (ATS) International Conference

New Data To Be Presented Show Reduction in ER Visits and Hospitalizations in Patients with Varying Levels of Disease Severity Following Use of Two Asthma Therapies JERUSALEM--(BUSINESS WIRE)--May 17, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced that eight company-sponsored abstracts will be presented at the 2017 American Thoracic Society (ATS) International Conference in Washington, D.C. on May 19-24, 2017. Data to be presented include three abstracts on CINQAIR® (reslizumab) Injection, an interleukin-5 antagonist monoclonal antibody (IgG4 kappa) approved by the U.S. ...
17.05.2017

Teva to Present Data for Deutetrabenazine in Tardive Dyskinesia at the American Psychiatric Association 2017 Annual Meeting

Data contribute to growing body of evidence supporting the development of deutetrabenazine for the treatment of tardive dyskinesia JERUSALEM--(BUSINESS WIRE)--May 17, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced eight abstracts evaluating deutetrabenazine tablets – formerly referred to as SD-809 – for the treatment of tardive dyskinesia (TD) will be presented at the American Psychiatric Association (APA) 2017 Annual Meeting in San Diego, CA from May 20-24. The data to be presented underscores the company’s efforts to advance research and treatment of patients with TD. “The ...
15.05.2017

Teva Announces Launch of Generic Glumetza® in the United States

JERUSALEM--(BUSINESS WIRE)--May 15, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of generic Glumetza®1 (metformin hydrochloride extended-release tablets), 500 mg and 1000 mg, in the U.S. Metformin hydrochloride extended-release tablets are used with diet and exercise to help control high blood sugar in adults with type 2 diabetes mellitus. Metformin hydrochloride extended-release tablets are not for people with type 1 diabetes or for people with diabetic ketoacidosis. More than 28 million people in the U.S. are living with type 2 diabetes2; a serious disease that can...
15.05.2017

Otsuka and Teva Sign Licensing Agreement for Japan on Prophylactic Migraine Drug Candidate Fremanezumab (TEV-48125)

TOKYO & JERUSALEM--(BUSINESS WIRE)--May 15, 2017-- Otsuka Pharmaceutical Co., Ltd (Otsuka) and Teva Pharmaceutical Industries, Ltd. (Teva) announce an agreement covering Japan for Otsuka to develop and commercialize Teva’s investigational drug candidate fremanezumab (TEV-48125), an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for the prevention of migraine. Fremanezumab is administered monthly as a subcutaneous injection. Through the agreement, Otsuka secures exclusive rights in Japan to fremanezumab, which Teva is globally developing in other countries. The annual prevalence of migraine in Japan is 8.4...
11.05.2017

Teva Reports First Quarter 2017 Financial Results

JERUSALEM--(BUSINESS WIRE)--May 11, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended March 31, 2017.     Revenues $5.6 billion   Cash flow from operations $0.5 billion ...
05.05.2017

Teva and Active Biotech Announce CONCERTO trial of Laquinimod in RRMS Did Not Meet Primary Endpoint

JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--May 5, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced results from the CONCERTO trial in patients with relapsing-remitting multiple sclerosis (RRMS). The primary endpoint in CONCERTO -- the evaluation of laquinimod (0.6 mg/daily capsules) versus placebo to evaluate the time to Confirmed Disability Progression (CDP) after at least 3 months – was not met. (Hazard Ratio of 0.937, p = 0.7057). Other data details announced by the Company show that on the secondary endpoint which measured change in brain vol...
05.05.2017

Teva Announces Publication of COPAXONE® (glatiramer acetate injection) Pregnancy Data in the International Journal of MS Care

JERUSALEM--(BUSINESS WIRE)--May 5, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that data suggests that women with relapsing forms of multiple sclerosis (RMS) who were exposed to COPAXONE® 20 mg/mL daily during pregnancy are not at higher risk for congenital anomalies compared to reference rates for abnormal pregnancy outcomes reported in two large databases representing the general population. These data appeared as an “Online First” article on the Website of the International Journal of MS Care (IJMSC) and represent the largest published analysis of pregnancy pharmacovigilance data for an RMS...
27.04.2017

Teva Announces Publication of ARM-TD Study Results in Neurology® for the Investigational Use of Deutetrabenazine in Tardive Dyskinesia

JERUSALEM--(BUSINESS WIRE)--Apr. 27, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced the publication of results from the Phase II/III study ARM-TD (Aim to Reduce Movements in Tardive Dyskinesia) in Neurology®, the medical journal of the American Academy of Neurology. The ARM-TD study evaluated the safety and efficacy of the investigational use of deutetrabenazine (SD-809) compared to placebo in the treatment of moderate to severe tardive dyskinesia (TD). “Tardive dyskinesia is a chronic and debilitating condition that affects patients who are already suffering from significant...
26.04.2017

Teva Announces Launch of Generic Vytorin® in the United States

JERUSALEM--(BUSINESS WIRE)--Apr. 26, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced the launch of generic Vytorin®1 (ezetimibe and simvastatin) tablets in the U.S. Ezetimibe and simvastatin tablets are a prescription medicine that contains two (2) cholesterol lowering medicines, ezetimibe and simvastatin, which are used along with diet to: Lower the level of “bad” cholesterol (low density lipoprotein cholesterol or LDL) Increase the level of “good” cholesterol (high density lipoprotein cholesterol or HDL) Lower the le...
26.04.2017

Teva Announces Planned Departure of Eyal Desheh, Group Executive Vice President and Chief Financial Officer

JERUSALEM--(BUSINESS WIRE)--Apr. 26, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today confirmed that Eyal Desheh, Group Executive Vice President, Chief Financial Officer, will depart from Teva during the coming months. The Company will immediately commence a search to identify a successor to serve as Chief Financial Officer. Mr. Desheh will take part in the company’s upcoming Q1 earnings call on May 11th. Mr. Desheh, 65, became Group Executive Vice President, Chief Financial Officer in 2008. From October 2013 to February 2014, Mr. Desheh served as Acting President and Chief Executive Officer. Earlier ...